---
title: "Stoke Therapeutics, Inc. (STOK.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/STOK.US/overview.md"
symbol: "STOK.US"
name: "Stoke Therapeutics, Inc."
parent: "https://longbridge.com/zh-CN/quote/STOK.US.md"
datetime: "2026-04-05T01:10:11.009Z"
locales:
  - [en](https://longbridge.com/en/quote/STOK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/STOK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/STOK.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/STOK.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/STOK.US/overview.md)


# Stoke Therapeutics, Inc. (STOK.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Biotechnology |
| 交易所 | US Market |
| 地址 | 45 Wiggins Avenue, Bedford, Massachusetts, United States |
| 官网 | [www.stoketherapeutics.com](https://www.stoketherapeutics.com) |

## 公司简介

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Ian F. Smith | CEO & Director |
| Arthur O. Tzianabos | Chairman of the Board |
| Adrian R. Krainer | Co-Founder & Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Edward M. Kaye | Advisor & Director |
| Barry S. Ticho | Chief Medical Officer |
| Arthur A. Levin | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| FMR LLC | 9.47% | 2025-12-31 |
| RTW Investments, LP | 9.38% | 2025-12-31 |
| Lynx1 Capital Management LP | 9.14% | 2025-12-31 |
| BlackRock, Inc. | 8.81% | 2025-12-31 |
| Redmile Group, LLC | 6.82% | 2025-12-31 |
| Morgan Stanley | 5.95% | 2025-12-31 |
| Baker Bros. Advisors LP | 5.64% | 2025-12-31 |
| The Toronto-Dominion Bank | 5.36% | 2025-12-31 |
| Cowen Inc. | 5.36% | 2025-09-30 |
| The Vanguard Group, Inc. | 5.32% | 2025-12-31 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| Pharmaceuticals | 184420000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Stoke Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Pharmaceuticals",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| North America | 184420000 | 100% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**